When the exposure amount is 0.12~0.27 times the recommended amount of the human body, there are too few spermatogenic epithelial cells in male dogs, and shed spermatogenic epithelial cells can be seen in the epididymis.

This data can cause the same damage when it is 0.02-0.09 times within lenvatinib.

In monkeys and rats, when the exposure amount was 0.4 to 1.91 times and 60 to 131 times the clinically recommended dose, ovarian follicle atresia can be seen in monkeys and rats.

The data for lenvatinib is 0.2 to 0.8 times, 10 to 44 times.

This result has excited all researchers.

Even compared with lenvatinib, which is twice as expensive as sorafenib, compound No. 7 has less impact on fertility and less damage to the human body!

The subsequent research on embryonic development toxicity, the study of toxicity in juvenile animals, carcinogenicity and various acute toxicities, mutagenicity, hepatotoxicity, cardiotoxicity, etc., were unexpectedly good.

Pharmacokinetic results were also released immediately.

Compound No. 7 was subjected to four sets of drug coupon experiments, namely healthy adult subjects, liver insufficiency, renal insufficiency and solid liver cancer tumor adult subjects.

Data shows that at the absorption level, after oral administration, compound No. 7 is rapidly absorbed and can reach its peak within one to four hours after administration.

Moreover, food does not affect absorption and cannot slow down the absorption rate.

Material balance research data show that the absolute bioavailability of this compound is about 95%.

And this data is 75%!

The distribution performance after absorption is also excellent. Its in vitro binding law with human plasma proteins is very high, ranging from 98% to 99%, mainly binding to albumin, and can also slightly bind to α1-acid glycoprotein and γ-globulin...

In vitro transporter research, safety pharmacology, elimination, and data are released immediately.

Compound No. 7 performed exceptionally well!

Although it is better than the sky-high magical drugs such as sorafenib and lenvatinib, it has more outstanding performance in some aspects, such as side effects, utilization, etc....

This has surprised Han Chang and others.

Sorafenib is an old-fashioned magical drug for liver cancer. It costs more than 10 billion yuan, and it took ten years to finally come out.

As for lenvatinib, Eisai Co., Ltd. spent fifteen years of research and development, and stopped all projects. It was only to sharpen this sword that he finally took part of the country from sorafenib.

In contrast, what about compound No. 7?

In less than four months, I spent 3.9 billion Daxia coins, which was not even a fraction of the other party. However, I successfully qualified to compete with sorafenib and lenvatinib, which is a miracle!

...

In one week, compound No. 7 quickly completed preclinical experiments.

Xu Qiu quickly submitted an application for clinical research on new drugs.

The relevant materials have been prepared long ago.

It includes materials that have been conducted in previous experiments, where and when human experiments will be conducted, as well as new compounds structures, administration methods, toxicology research reports, etc.

As soon as this document left Baiyu Pharmaceutical Factory, it was immediately marked with a confidential label and escorted by a special person. He took a special plane to Tiandu that day.

Tiandu, the Drug Administration, the Ethics Review Committee, etc. are already ready.

Also attending the meeting were the Minister of Health and the Director of the Health Commission.

The conference room was not calm at this time, and the big guys who could determine the direction of the medical industry were whispering to each other and discussing this matter.

"It really happened?"

"Clinical human experiments have begun, what are the results?"

"I don't know that all the new liver drug research and development departments are Xu Qiu's researchers, and we don't know the internal news..." The speaker glanced at the Minister of Health.

With what he said back then, no one dared to interfere with Xu Qiu, let alone arrange personnel to collect information.

Therefore, everyone knows nothing about the various results, data, etc. of compound No. 7.

Even the code name "Compound No. 7" was learned by the Drug Administration from the last approval of the new drug for experimental use.

“Sent here…”

As soon as he finished speaking, the specialist of the Ministry of Health brought a briefcase into the conference room.

Bang.

A heavy briefcase was placed in front of the Minister of Health.

He nodded, entered the password, unlocked it layer by layer and took out the innermost file, checked Xu Qiu's signature at the seal, and then nodded.

The ones sent to the headquarters include all internal secrets of Compound No. 7, and once they are leaked, the consequences will be unimaginable.

They are not allowed to be careless!

"No problem, please review it."

The Minister of Health took out the most critical compounds structures, manufacturing processes, etc.

If it is just an ordinary generic drug or original drug, there is no need to be too vigilant, after all, those who can participate in the conference are all their own people.

But compound No. 7 is too important, and they are unwilling to bet!

Therefore, only he, the Director of the Drug Administration and a few people can read these documents.

...

The conference room was quiet, and everyone was carefully examining the various data submitted by the new liver medicine department.

Everyone's expressions gradually changed from curiosity to solemnity, and finally changed into solemn expressions, even with a hint of confusion.

"This...is really the pre-experimental data for compound No. 7?"

"How is it possible, it's a result of more than four months, compared to sorafenib?"

"It's not just over four months, he only used 5 billion! No, the 5 billion is not used up yet!"

"No, he is really here? It's really five billion?"

"Xu Qiuming clearly agreed to make a safe version of the liver peaceful, why did he silently throw the other party a street... This data is countless times better than Huining's ideal liver peaceful!"

Everyone's eyes fell on the Minister of Health and the Director of the Health Commission.

That look seemed to be questioning: This is the person you two recommend, please give a reasonable explanation...ωωw..net

The smile at the corner of the Minister of Health's mouth was almost impossible to suppress. As soon as he lay back, his tense mood also relaxed and said, "I can't explain, this is Xu Qiu!"

The director of the Health Commission also smiled and sighed: "Yes, this is Xu Qiu!"

...

The next day, an urgent approval was sent back to Linhai City.

After certification, all reviewed and approved by the Drug Administration, the Ethics Approval Committee, etc., the No. 7 compound is allowed to conduct clinical trials!

Xu Qiu's speed was faster. One hour later, the recruitment notice for the first phase clinical trial was released on official websites such as Linyi, Linhai City, and Baiyun Province!

"Hepatic cancer is a serious disease with a high recurrence rate and a poor prognosis. The five-year survival rate of patients with lymph node spread is only 11%; after spreading to other organs, it is less than 3%.

"As a major hepatitis B country, the incidence of liver cancer in my country is high. Among men, liver cancer is second only to lung and gastric cancer, ranking third most prevalent cancer.

"But at present, our effective treatment methods for liver cancer are still extremely limited!

"The existing systemic therapies for liver cancer are divided into two categories. One is immunotherapy and the other is multikinase inhibitor (Mki). However, mki drugs such as sorafenib and lenvatinib are priced extremely high, with a single box price of up to more than 20,000 yuan, and a month's treatment cost is about 50,000 yuan, or even higher!
Chapter completed!